Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...
The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback